Media stories about CONMED (NASDAQ:CNMD) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CONMED earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 46.3253098879209 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- CONMED Co. (CNMD) Declares $0.20 Quarterly Dividend (americanbankingnews.com)
- Champlain Investment Partners LLC Has $75.31 Million Stake in CONMED Co. (CNMD) (americanbankingnews.com)
- Conmed Corp (CNMD) Files 10-K for the Fiscal Year Ended on December 31, 2017 (finance.yahoo.com)
- $0.43 EPS Expected for CONMED Co. (CNMD) This Quarter (americanbankingnews.com)
A number of analysts have commented on CNMD shares. Needham & Company LLC upped their price target on shares of CONMED from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Zacks Investment Research raised shares of CONMED from a “hold” rating to a “buy” rating and set a $57.00 price target on the stock in a research report on Wednesday, January 3rd. KeyCorp reaffirmed a “hold” rating on shares of CONMED in a research report on Friday, November 3rd. Piper Jaffray Companies reissued a “hold” rating and set a $46.00 price objective on shares of CONMED in a research report on Friday, November 3rd. Finally, BidaskClub raised shares of CONMED from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $59.00.
CONMED (NASDAQ:CNMD) last released its quarterly earnings data on Wednesday, January 31st. The medical technology company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.04. The company had revenue of $222.60 million for the quarter, compared to analysts’ expectations of $212.17 million. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.54 EPS. research analysts forecast that CONMED will post 2.14 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 15th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.32%. CONMED’s dividend payout ratio (DPR) is presently 40.82%.
In other news, Director Jo Ann Golden sold 3,000 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $63.90, for a total transaction of $191,700.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Luke A. Pomilio sold 1,962 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $60.25, for a total transaction of $118,210.50. The disclosure for this sale can be found here. Insiders have sold a total of 22,985 shares of company stock worth $1,452,208 in the last three months. Insiders own 2.62% of the company’s stock.
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.